Spero Therapeutics Licenses Immunology Drug Candidate From Innovent, Recieves $105 Million Financing

PartnershipPositive

AI Analysis

Summary

Spero Therapeutics licensed an immunology drug candidate from Innovent and received $105 million in financing. The deal represents a significant partnership and capital infusion for Spero's pipeline expansion.

Importance:7/10

Sentiment:

0.60

licensingimmunologyfinancingpartnership

Related Companies

$IVBXF

Read the original article

Published by yahoo_finance on July 14, 2026 10:46 AM

Read Original